Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Advanced Accelerator Application SA (ADR) (AAAP) Expands Pipeline With NeoBOMB1

Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) has announced the expansion of its theranostic pipeline with the addition of NeoBOMB1, which it describes as a novel GRPR antagonist. The compound is being evaluated as a potential treatment for prostate cancer, breast cancer and gastrointestinal stromal tumor.

According to Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP), NeoBOMB1 recently underwent two independent studies that evaluated the compound on prostate cancer patients. The company is preparing to present data on the two studies at the upcoming annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The event will take place next week in San Diego, California. AAAP’s presentation on NeoBOMB1 will be on June 14 and 15.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, internet, male, drugstore, service,

wavebreakmedia/Shutterstock.com

A promising compound

Listening to Advanced Accelerator Application’s management speak about NeoBOMB1, one may get the feeling that they are confident that they have a promising cancer compound in the works. In a statement, the company said that NeoBOMB1 is capable of binding selectively and with great affinity to the GRP receptors that are expressed by many types of tumors. The company went further to say that the receptors that NeoBOMB1 has shown have an ability to bind with important targets when it comes to dealing with diagnostic and therapeutic issues around various cancers.

Based on a successful formula

According to AAAP’s CEO Stefano Buono, NeoBOMB1 is based on the same successful formula that has been applied in the development of lead compounds Lutathera and Somakit. It is worth pointing out that Somakit was recently cleared by the FDA.

THe company acquired rights to NeoBOMB1 from the original developers at Demokritos and Erasmus University Medical Center. The company is planning additional studies on the compound to assess how it performs in relation to prostate cancer, breast cancer and gastrointestinal stromal tumor.

Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) generated revenue of about $30.7 million in 1Q2016, up nearly 30% YoY. Its net loss of $3.39 million in the latest quarter shrank from a net loss of $6.72 million in the comparable period a year ago.

Note: This article is written by Adam Russell and originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!